2021 WCLC Highlights

CME

Independent Conference Coverage of the IASLC 2021 World Conference on Lung Cancer

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: November 18, 2021

Expiration: November 17, 2022

Anne Chiang
Anne Chiang, MD, PhD
Thomas Stinchcombe
Thomas Stinchcombe, MD

Activity

Progress
1
Course Completed
Introduction

In this module, Anne Chiang, MD, PhD, and Thomas Stinchcombe, MD, discuss key findings in lung cancer presented at the IASLC 2021 World Conference on Lung Cancer (WCLC), including updates in small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), both for early-stage and advanced disease.

Please note that the key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with lung cancer do you provide care for in a typical month?

Based on currently available data and approved indications, which of the following immune checkpoint inhibitors would be an appropriate treatment option for a patient with locally advanced, unresectable NSCLC who is not a candidate for definitive chemoradiation and whose tumor biopsy showed high PD-L1 expression ≥50% and no targetable EGFR or ALK mutations?

Which of the following results was reported by Spira and colleagues with the use of mobocertinib in a cohort of patients with refractory EGFR ex20ins mutation–positive advanced NSCLC and a response or stable disease of at least 6 months to a previous EGFR TKI?

At the WCLC 2021 annual meeting, Spira and colleagues reported new early evidence of antitumor activity for the recently approved agent, amivantamab, in patients with advanced NSCLC and which of the following biomarkers?

Which of the following results was reported by Garon and colleagues at WCLC 2021 from the NSCLC patient cohort of the phase I dose-escalation/dose-expansion TROPION-PanTumor01 study evaluating datopotamab deruxtecan, an investigational antibody–drug conjugate targeting TROP2?